Reference : L’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexav...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Human health sciences : Oncology
Human health sciences : Surgery
http://hdl.handle.net/2268/1203
L’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexavar) :Résultats de l’étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol)
French
[en] Study of the Month. Palliative management of hepatocarcinoma with Sorafenib (Nexavar) : Results of the SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol) trial
Detry, Olivier mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Delwaide, Jean mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Deroover, Arnaud mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Meunier, Paul mailto [Centre Hospitalier Universitaire de Liège - CHU > > Imagerie médicale >]
Lamproye, Anne [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Honore, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Polus, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Mar-2009
Revue Médicale de Liège
Hopital de Baviere
64
3
168-170
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] Liver transplantation ; cancer ; oncology ; hepatectomy ; radiofrequency ablation
[en] Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that Sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 months, without any radiologic response or improvement in the delay before symptomatic progression of the disease. The monthly cost of Sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of Sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liège is taking part to a randomized, multicentric study evaluating the use of Sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of Sorafenib with other antitumoral agents.
Professionals ; Students ; General public
http://hdl.handle.net/2268/1203

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Sorafenib.2009.RMDLg.HCC.pdfNo commentaryPublisher postprint317.37 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.